Programmed Cell Death 1 (PD-1; CD279) is the best characterized and studied immune checkpoint receptor in cancer, with PD-1 inhibitors showing strong antitumor activity in several cancer settings including melanoma and Non-Small Cell Lung Cancer (NSCLC) [33,34]. This evidence concerns the gene PDCD1 and melanoma.